Targeted Therapy for Non-Small Cell Lung Cancer
This article aims to contextualize recent research and provide an updated summary of targeted therapies available for patients with NSCLC. With practitioners and clinical researchers in mind, we note standard of care therapies, important approvals, practice guidelines, and treatments in development. The first section discusses mutations in the epidermal growth factor receptor (EGFR) gene, and the second section examines rearrangements in the anaplastic lymphoma kinase (ALK) and ROS1 fusions. Finally, we explore the rarer molecular alterations in BRAF, RET, MET, HER2, and KRAS. Given the many available therapies, it is important to understand the molecular alterations in NSCLC, and how to target them. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents | Abstract | Full text
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Noor, Zorawar S. Cummings, Amy L. Johnson, McKenna M. Spiegel, Marshall L. Goldman, Jonathan W. Tags: Review Article Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | HER2 | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Respiratory Medicine